Risk of Serious Neutropenic Events in Cancer Patients Treated with Bevacizumab: A Meta-analysis

Zhou, Fan; Shao, Jiang-Hua; Wu, Lin-Quan; Yin, Xiang-Bao; Yu, Xin

추천

검색

자료유형: 학술저널

저자정보: Zhou, Fan (Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital of Nanchang University) Shao, Jiang-Hua (Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital of Nanchang University) Wu, Lin-Quan (Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital of Nanchang University) Yin, Xiang-Bao (Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital of Nanchang University) Yu, Xin (Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital of Nanchang University)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제14권 제4호

발행연도: 2013.1

수록면: 2,453 - 2,459 (7page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Bevacizumab has been approved for use in combination with chemotherapy to treat many types of cancer but associated neutropenic events, including febrile neutropenia, have been reported. To estimate the incidence and relative risk of neutropenic events in cancer patients treated with bevacizumab combination therapy, we searched PubMed, EMBASE, and Web of Science literature databases, as well as abstracts presented at the American Society of Clinical Oncology conferences, to identify relevant studies published from January 1966 to December 2011. Studies that compared bevacizumab plus chemotherapy or biological therapy with chemotherapy or biological therapy alone, and that had adequate safety data profiles, were selected for analysis. Statistical analyses were conducted to calculate the summary incidence rates, relative risks (RRs), and 95% confidence intervals (CIs) using fixed- or random-effects models. A total of 22 clinical trials involving 15,056 patients were included in the analysis. The summary incidences of high-grade neutropenia (HGN) and high-grade febrile neutropenia (HGFN) in patients receiving bevacizumab was 27.3% (95% CI: 26.4%-28.3%) and 3.91% (95% CI: 3.51%-4.37%), respectively. The risks of HGN (RR=1.10; 95% CI: 1.02-1.19; P=0.02) and HGFN (RR=1.31; 95% CI: 1.08-1.59; P=0.005) were significantly increased in bevacizumab-treated patients, compared to those who did not receive bevacizumab. The RR of bevacizumab-associated HGN, but not HGFN, varied significantly with tumor types (P=0.005). The increased risk of bevacizumab-associated neutropenic events was dose-dependent, as the RR was greater at a dose of 5 mg/kg/week than at 2.5 mg/kg/week. Our findings suggest that bevacizumab addition to cancer therapy significantly increases the risk of serious neutropenic events, and this risk may be dose-dependent.

#Bevacizumab #neutropenia #febrile neutropenia #cancer #meta-analysis

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요